Helen Torley - 15 Feb 2024 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ James R. Oehler, Attorney-in-Fact
Issuer symbol
HALO
Transactions as of
15 Feb 2024
Net transactions value
-$885,361
Form type
4
Filing time
16 Feb 2024, 17:39:34 UTC
Previous filing
13 Feb 2024
Next filing
20 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Options Exercise $0 +13,092 +2.1% $0.000000 651,096 15 Feb 2024 Direct
transaction HALO Common Stock Tax liability $252,663 -7,036 -1.1% $35.91 644,060 15 Feb 2024 Direct F1
transaction HALO Common Stock Award $0 +32,781 +5.1% $0.000000 676,841 15 Feb 2024 Direct F2
transaction HALO Common Stock Tax liability $632,698 -17,619 -2.6% $35.91 659,222 15 Feb 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Restricted Stock Units Options Exercise $0 -13,092 -50% $0.000000 13,092 15 Feb 2024 Common Stock 13,092 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported disposition of 7,036 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.
F2 This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.
F3 The reported disposition of 17,619 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.
F4 This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.